http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012104639-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate | 2010-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012104639-A |
| titleOfInvention | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF POST-PRANDRANDIAL HYPERGLYCEMIA TYPE II DIABETES BY INTRODUCTION THROUGH THE MURAL ORAL CAVITY |
| abstract | 1. A pharmaceutical composition, characterized in that it has the form of an aqueous-alcoholic solution in which at least one hypoglycemic / insulinotropic active substance is stably and completely dissolved in a dosage reduced by at least 30-50% compared to a conventional a single dose for oral administration, for its use by administration through the mucous membrane of the oral cavity as a medicine in the precise treatment of postprandial hyperglycemia of type II diabetes in humans or animals. 2. The pharmaceutical composition according to claim 1, wherein the strength is at least 30 °. The pharmaceutical composition according to claim 1 or 2, which is based on water and ethanol. The pharmaceutical composition according to claim 1 or 2, wherein the hypoglycemic active ingredient is present in base form and / or in salt form. The pharmaceutical composition according to claim 1 or 2, which has the form of an aqueous-alcoholic solution with a volume of less than 2 ml, in which an amount less than or equal to 250 mg of at least one hypoglycemic active substance is stably and completely dissolved. The pharmaceutical composition according to claim 1 or 2, in which the hypoglycemic active ingredient in a dosage reduced by 30-50% compared with the usual single dose when administered orally, is selected from among lipophilic or amphiphilic active substances, such as glycazide, metformin, glibenclamide, clayey and incretins. 7. The pharmaceutical composition according to claim 1 or 2, which further comprises a pH adjusting agent. The pharmaceutical composition according to claim 7, in which the pH-adjusting substance is selected from among carbonates and bicarbonates |
| priorityDate | 2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.